Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 31;101(3):adv00422.
doi: 10.2340/00015555-3712.

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Marina Talamonti  1 , Giovanna Malara, Ylenia Natalini, Federico Bardazzi, Andrea Conti, Andrea Chiricozzi, Cristina Mugheddu, Paolo Gisondi, Stefano Piaserico, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Anna Balato, Francesco Loconsole, Annamaria Offidani, Claudio Bonifati, Francesca Prignano, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo; the SUPREME Study Group
Affiliations
Clinical Trial

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study

Marina Talamonti et al. Acta Derm Venereol. .

Abstract

This study evaluated whether secukinumab treatment for patients with moderate to severe plaque psoriasis correlates with improvements in symptoms of anxiety and depression. SUPREME was a 24-week, phase IIIb, multicentre, prospective study conducted across 50 centres in Italy with an extension period of up to 72 weeks. Assessments used were: Psoriasis Area Sever-ity Index (PASI), Hospital Anxiety and Depression Scale (HADS) - Anxiety (HADS-A), and HADS - Depression (HADS-D) scores and Dermatology Quality Life Index (DLQI). Compared with baseline, a significantly greater proportion of patients who reported moderate to severe clinical symptoms of anxiety or depression (HADS-A or HADS-D ≥ 11) were free of moderate to severe symptoms at weeks 16 and 48. The PASI and DLQI scores reduced over time with secukinumab treatment. Psoriasis treatment with secukinumab for 48 weeks resulted in significantly improved skin clearance and a parallel improvement in symptoms of anxiety and depression, assessed by HADS.

Keywords: depression; psoriasis; quality of life; secukinumab; anxiety.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: AC served as advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme and UCB Pharma. GP has been speaker and consultant for Novartis and AbbVie. PA received honoraria for speaker from AbbVie, Janssen, Eli Lilly, Novartis, Pfizer, Celgene and Sanofi. MCF has served as a speaker, board member and/or received research grants from Abbvie, Leo Pharma, Celgene, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi-Genzyme. AC has been an advisory board member and consultant, and has received fees and honoraria or has participated in clinical trials for AbbVie, Biogen, Leo Pharma, Eli Lilly, Novartis, UCB-Pharma, Sandoz, and Janssen Cilag. PG has been a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, Leo-pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. AO acted as a speaker and consultant for AbbVie, Eli Lilly, Novartis, Celgene, Sanofi, Galderma, Leo Pharma, Pierre Fabre, outside of the present work. FP reports personal fees for advisory board from AbbVie, Biogen, Eli Lilly, Celgene, Leo Pharma, Novartis, Sanofi and Janssen-Cilag, outside of the present work. SP has consulted (includes advisory boards and podium presentations) for AbbVie, Almirall, Celgene, Galderma, Janssen-Cilag, Leo Pharma, Lilly, MSD, Novartis and UCB Pharma. MT, GM, YN, FB, CM, FC, CP, AB, CB and FL report no conflict of interest. AC acted as a speaker and consultant for AbbVie, Eli Lilly, Novartis, Almirall, Celgene, Sanofi, Janssen and Pfizer. MB, AR, EA and RO are employed by Novartis.

SUPREME Study Group: Luca Bianchi, Valeria Brazzelli, Cinzia Buligan, Martina Burlando, Giacomo Caldarola, Anna Campanati, Angelo Cattaneo, Francesco Cusano, Paolo Dapavo, Stefano Dastoli, Clara De Simone, Micol Del Giglio, Vito Di Lernia, Sergio Di Nuzzo, Daniele Dusi, Rosaria Fidanza, Maria Laura Flori, Chiara Franchi, Marco Galluzzo, Alberto Ghilardi, Giampiero Girolomoni, Federica Giuliani, Dario Graceffa, Katharina Hansel, Piergiorgio Malagoli, Valentina Mastrandrea, Matteo Megna, Santo Raffaele Mercuri, Maria Letizia Musumeci, Luigi Naldi, Alessandra Narcisi, Diego Orsini, Manuela Papini, Annalisa Patrizi, Monica Pau, Giovanni Pellacani, Ketty Peris, Severino Persechino, Leonardo Pescitelli, Lucia Pietroleonardo, Alberto Reseghetti, Marco Romanelli, Franco Rongioletti, Filomena Russo, Roberta Scuderi, Riccardo Sirna, Nevena Skroza, Giuseppe Stinco, Luca Stingeni, Sara Trevisini, Marina Venturini, Cristina Zane, Leonardo Zichichi, Antonio Zini.

Figures

Fig. 1
Fig. 1
Patient disposition by study cohort (1-year population). HADS-A/D: Hospital Anxiety and Depression Scale – Anxiety/Depression subscale; N: total number of patients; n: number of patients.
Fig. 2
Fig. 2
Psoriasis Area and Severity Index (PASI) score over time: mean score by (a) anxiety and (b) depression status (1-year population). HADS-A/D: Hospital Anxiety and Depression Scale – Anxiety/Depression subscale.
Fig. 3
Fig. 3
Prevalence of (a) anxiety and (b) depression: baseline vs follow-up visits. *p < 0.001 and p < 0.001 vs baseline. HADS-A/D: Hospital Anxiety and Depression Scale – Anxiety/Depression subscale. HADS-A or D ≥ 11: no moderate to severe anxiety or depression; HADS-A or D < 11: moderate to severe anxiety or depression.
Fig. 4
Fig. 4
Relationship between anxiety and depression status by baseline and Dermatology Life Quality Index (DLQI) scores: (a) DLQI score by anxiety status over time; (b) DLQI score by depression status over time.
Fig. 5
Fig. 5
Proportion of patients with Dermatology Life Quality Index (DLQI) score of 0 or 1 by anxiety or depression status. (a) DLQI 0/1 by anxiety status overtime; (b) DLQI 0/1 by depression status over time.
See this image and copyright information in PMC

References

    1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–271. - PubMed
    1. Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care 2016; 22: s216–224. - PubMed
    1. Kimball AB, Leonardi C, Stahle M, Gulliver W, Chevrier M, Fakharzadeh S, et al. . Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol 2014; 171: 137–147. - PMC - PubMed
    1. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891–895. - PMC - PubMed
    1. Wu JJ, Feldman SR, Koo J, Marangell LB. Epidemiology of mental health comorbidity in psoriasis. J Dermatolog Treat 2018; 29: 487–495. - PubMed

Publication types